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This work investigates the metabolic origin of triacylglycerol
(TAG) formed during lipid droplet (LD) biogenesis induced by
stress. Cytotoxic inhibitors of fatty acid synthase induced TAG
synthesis and LD biogenesis in CHO-K1 cells, in the absence of
external sources of fatty acids. TAG synthesis was required for
LD biogenesis and was sensitive to inhibition and down-regula-
tion of the expression of group VIA phospholipase A2 (iPLA2-
VIA). Induction of stress with acidic pH, C2-ceramide, tunica-
mycin, or deprivation of glucose also stimulated TAG synthesis
and LD formation in a manner dependent on iPLA2-VIA. Over-
expression of the enzyme enhanced TAG synthesis from endog-
enous fatty acids and LD occurrence. During stress, LD biogen-
esis but not TAG synthesis required phosphorylation and
activation of group IVA PLA2 (cPLA2). The results demon-
strate that iPLA2-VIA provides fatty acids for TAG synthesis
while cPLA2 allows LDbiogenesis. LD biogenesis during stress
may be a survival strategy, recycling structural phospholipids
into energy-generating substrates.
Intracellular lipid droplets (LDs)5 are cytosolic inclusions
present in most eukaryotic cells, containing a core of triacylg-
lycerol (TAG) and cholesteryl esters, surrounded by a phospho-
lipid monolayer and by specific proteins, among which the best
characterized belong to the perilipin family (1–3). The biology
of LD has received increasing interest, due to the link between
excess lipid storage in certain tissues and pathologies such as
obesity, diabetes, or atherosclerosis (3, 4). LDs have been shown
to interfere with membrane translocation of the insulin-sensi-
tive glucose transporter, an observation that might account for
insulin resistance in type 2 diabetes (5). The recent identifica-
tion of 132 genes controlling LD number, size, and distribution
in Drosophila (6) illustrates the complexity of this organelle,
whose dynamic nature is far from being understood fully.
LDs are formed in two very different environmental condi-
tions and, presumably, the physiological significance in each
case is different. First, cells accumulate LD in response to exog-
enous lipid availability (4), present in serum lipoproteins or as
free fatty acids. There is general agreement that LD content
arising from the medium has a storing purpose for energy gen-
eration and membrane building. Using this experimental para-
digm of exogenous lipid loading, we have shown the implica-
tion of group IVA PLA2 (cPLA2) in LD biogenesis at a step
beyond the synthesis of TAG (7). Second,many kinds of cellular
stress, including inflammation, apoptosis induced by different
insults or contact inhibition, also induce LD biogenesis. An
account of this situation is the human T lymphoblastoid cell
line (HuT 78) undergoing apoptosis triggered by Fas antibody
(8). In these cases, the metabolic origins of LD-associated neu-
tral lipids and the physiological function they subserve are not
known.
Altering phospholipid metabolism has been shown to cause
programmed cell death in some instances (9–12), and, con-
versely, programmed cell death often alters phospholipid
metabolism, resulting in the accumulation of lysophospholip-
ids and fatty acids (13). Current evidence suggests that group
VIA PLA2 (iPLA2-VIA) is involved in the generation of lyso-
phosphatidylcholine during programmed cell death, which
maymediate attraction and recognition/engulfment signals for
apoptotic cell clearance by phagocytes (13–17). Unlike cPLA2,
which shows a marked preference for arachidonic acid-con-
taining phospholipids, iPLA2-VIA has no substrate specificity
regarding the fatty acid residue at the sn-2 position, and its
implication in eicosanoid synthesis may be minor. Instead, the
enzyme has a housekeeping role mediating phospholipid
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remodeling through deacylation/reacylation reactions (18).
Bearing this in mind, we hypothesized that during cellular
stress part of the fatty acids released by phospholipid degrada-
tion could be incorporated into TAG and stored in LD. In
essence, our results show that TAG synthesis associated with
the formation of LD during stress depends on iPLA2-VIA. Fur-
ther, we show that the implication of cPLA2 in LD formation
still holds in this new paradigm.
EXPERIMENTAL PROCEDURES
Materials—[5,6,8,9,11,12,14,15-3H]Arachidonic acid ([3H]-
AA, 200 Ci/mmol) was from American Radiolabeled Chemi-
cals, [9,10(n)-3H]palmitic acid (49 Ci/mmol) was from Amer-
shamBiosciences, and [1-14C]acetate (58mCi/mmol) was from
PerkinElmer Life Sciences. Bromoenol lactone (BEL), (S)-BEL,
(R)-BEL, and cerulenin were from Cayman Chemical Co., and
pyrrolidine-2 (py-2, cat. no. 525143)
andN-acetyl-D-sphingosine (C2-ce-
ramide) were from Calbiochem.
Rabbit anti-cPLA2 and anti-phos-
pho Ser505 cPLA2 antibodies were
from Cell Signaling, chicken anti-
ADRP from GenWay Biotech, rab-
bit anti-GAPDH from Ambion,
mouse anti-BiP/GRP78 from BD
Bioscience, rabbit anti-iPLA2-VIA
from Cayman, and rabbit anti-GFP
from Abcam. Tripalmitin, primu-
line, Nile Red, triacsin C, C75, tuni-
camycin, phorbol 12-myristate
13-acetate, and U73122 were from
Sigma-Aldrich, and 4,4-difluoro-
5-methyl-4-bora-3a,4a-diaza-s-in-
dacene-3-dodecanoic acid (C1-
BODIPY 500/510-C12) was from
Molecular Probes.
Constructs—The sequence of
human iPLA2-VIA2 was cloned in
the pEYEFP-N3 vector (Clontech),
using the HindIII and SalI restric-
tion sites. This construct encodes
the expression of a fluorescent
fusion protein containing N-termi-
nal iPLA2-VIA2 followed by
enhanced yellow fluorescent pro-
tein (EYFP).
Cells—CHO-K1 cells were cul-
tured as described (7). For the
experiments, cells were seeded at a
density of 30,000 cells/ml in 24- (0.5
ml) or 6-well (2ml) plates andmain-
tained in FBS-containing medium
for 24 h. Before LD induction, cells
were switched to serum-free
medium for 24 h to set control con-
ditions with minimal occurrence of
LD (7). When indicated, cells (40–
70% confluence) were transfected
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FIGURE 1. Cerulenin and C75 inhibit fatty acid synthesis. A, cells were
treated for 24 hwith cerulenin (open bars) or C75 (filled bars), and viabilitywas
determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide reduction assay. B, serum-starved cells were incubated with [14C]ac-
etate (2 Ci/ml, 34.4 M) for 6 h in the presence (filled bars) or absence (open
bars) of 5MtriacsinC (TRC) andwithorwithout30Mceruleninor 20MC75.
Lipids were separated by TLC, and areas of the silica co-migrating with pal-
mitic acid were counted. Results are means  S.E. of three independent
experiments each carried out with triplicate determinations. *, significantly
different (p 0.001) from controls treated only with TRC.
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FIGURE2. Inhibitionof fattyacid synthesis inducesLDbiogenesis.Cellswere left untreated (A) or treated for
6 h with 30 M cerulenin (B), 20 M C75 (C), or 7.5% FBS (D). LD occurrence was indirectly quantified by flow
cytometry (E). In this case, fluorescence intensities in FL1 were quantified as the median values of the event
distributions for each condition, expressed as the increase above the control, which averaged 434 9 (n 6).
Results are means S.E. obtained in six independent experiments. Panel F shows Western blots of ADRP and
GAPDH. Scale bar represents 10 m. *, significantly different (p 0.01) from controls.
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with 1 g of plasmid/ml (pGFP-C3
from Clontech or iPLA2-VIA2-
EYFP) using Lipofectamine PlusTM
(Invitrogen), following the manu-
facturer’s instructions.
Nile Red Staining and Fluores-
cence Microscopy—Cells cultured
on glass coverslips were washed
with phosphate-buffered saline
(PBS, Sigma-Aldrich), fixed with 3%
paraformaldehyde for 10 min, and
washed twice with PBS. Cells were
overlaidwith 0.5ml of PBS, towhich
2.5 l of a solution of Nile Red in
acetone (0.2 mg/ml) was added, so
that the final concentrations of Nile
Red and acetone were 1 g/ml and
0.5%, respectively. Samples were
kept in the dark until photographed
in a Leica Qwin 500 microscope
with a Leica DC200 camera, using
the LeicaDCviewer 3.2.0.0 software.
Flow Cytometry—Indirect quan-
tification of LD by flow cytometry in
Nile Red-stained cells was per-
formed exactly as described (7).
Briefly, paraformaldehyde-fixed
cells were stained with 1 g/ml Nile
Red during 45 min and analyzed
with a Cytomics FC 500 (Beckman
Coulter) equipped with an argon
laser (488 nm), in the FL1 channel
(505–545 nm). After gating out cel-
lular debris, 30,000 events where
acquired in all the assays, in linear
scale. Fluorescence intensities in the
different treatments were quanti-
fied as the median value of each dis-
tribution of events, and expressed as
increase above the median of the
control (serum-starved cells), which
do not contain LD (7).
[3H]AA Release—Serum-starved
cells, seeded in 24-well plates, were
labeledwith 0.25Ci of [3H]AA (0.5
Ci/ml) for 24 h, then washed once
with PBS, incubated 5 min with
Ham’s F-12 supplemented with 0.5
mg/ml albumin, and washed twice
morewith PBS (19). Radioactivity in
the last wash was subtracted from
released [3H]AA over the stimula-
tion period. At the end of the treat-
ments, culture media containing
released [3H]AA were taken, centri-
fuged, and counted. Cell monolay-
ers were detachedwith ice-cold PBS
containing 1% Triton X-100, and
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FIGURE 3. Cerulenin and C75 induce TAG synthesis from pre-existing fatty acids. A, cells were treated for
6 h with vehicle (lane 4), 30 M cerulenin (lane 5), 20 M C75 (lane 6), or 7. 5% FBS (lane 7), and lipids were
separated by TLC and stained with primuline. Lanes 1–3 contain 1, 5, and 10 g of tripalmitin standard. PL,
phospholipids; Cho, cholesterol; DAG, 1,2-diacylglycerol. B, densitometric quantification of TAG (means S.E.
of four independent experiments each carried out in triplicate). C and D, cells were labeled for 24 h with 0.5
Ci/ml (8.6 M) [14C]acetate (C) or 0.5 Ci/ml (10.2 nM) [3H]palmitic acid (D), washed, and treated with cerule-
nin, C75, or FBS for 6 h, then lipids were separated by TLC and radioactivity in TAG was counted. Results are
means S.E. of three independent experiments carriedout in triplicate. E and F, cellswere labeled for 24hwith
5 Ci/ml [3H]palmitic acid (1 M), then treated with vehicle (open bars) or with cerulenin (filled bars) for 6 h.
Radioactivity in TAG is shown in panel E, together with that in phospholipids (inset). After extraction of TAG
from the silica, acyl-ester bonds were hydrolyzed by methanolic KOH treatment. Panel F shows radioactivity
present in water-soluble and chloroform phases after alkaline deacylation of TAG. These chloroform phases
were concentrated and developed in TLC as shown in panel G, which represents radioactivity from control
(open circles) or cerulenin-treated samples (filled circles), together with that of a non-deacylated TAG sample
(dotted line). Radioactivity at Rf between 0.30 and 0.40 co-migrated with palmitic acid standard. *, significantly
different (p 0.01) from control. #, significantly different (p 0.01) from FBS.
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also counted for radioactivity to
monitor [3H]AA incorporation into
the cells.
Quantification of [3H]TAG—Se-
rum-starved cells, seeded in 24-well
plates, were labeled with [3H]palmi-
tate (usually 0.5 Ci/ml unless indi-
cated otherwise, equivalent to 10.2
nM) or with [14C]acetate (0.5
Ci/ml or 8.6 M) for 24 h, washed
twice with PBS and once with cul-
ture medium, and treated as
described in each experiment. Cells
were then harvested on ice and
washed with 1 ml of PBS, and lipids
were extracted (20). To separate the
major lipid species, the chloroform
phases were evaporated under vac-
uum, dissolved in 15 l of chloro-
form/methanol (3:1, v/v), and spot-
ted onto silica gel G TLC plates
(Merck), which were developed in
hexane/diethyl ether/acetic acid
(70:30:1, v/v), and stained with
primuline spray. Identification of
the major species was made by co-
migration with authentic standards.
Quantification of radioactive TAG
was done by scraping into vials the
silica gel from regions correspond-
ing to migration of the standards.
Primuline-stained TAGwas quanti-
fied by densitometric analysis after
acquiring images under UV light.
Alkaline Hydrolysis of [3H]TAG—
Serum-starved cells in 6-well plates
were labeled with [3H]palmitate (5
Ci/ml or 0.1 M) and treated with
cerulenin. Pooled lipid extracts
from6wells were separated byTLC.
Silica gel containing [3H]TAG was
scraped into glass tubes, and lipid
was extracted with 1 ml of chloro-
form/methanol (1:1, v/v). 2 ml of
chloroform and 0.5 ml of 1 M KOH
in methanol/water (19:1, v/v) were
added, and the tubes were left 1 h at
room temperature. After neutral-
ization with HCl, 2.5 ml of chloro-
form, 1.5ml ofmethanol, and 1.5ml
of water were added to split organic
and aqueous phases.
Immunoblots—Cells were lysed
with 62.5 mM Tris-HCl buffer, pH
6.8, containing 2% SDS, 10% glyc-
erol, 50 mM dithiothreitol, and
0.01% bromphenol blue, and 20 g
of protein was separated by stand-
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FIGURE4.TAGsynthesisandLDbiogenesisare independentof fattyacidsynthesis regardlessof thekind
of stress. Serum-starved cells (see Fig. 2A) were treated for 6 h with medium at pH 6 (A–C), with 20 M
C2-ceramide (D–F), 5 g/ml tunicamycin (G–I), or Krebs buffer without glucose (J–L), either in the absence or
presence of cerulenin (30 M) or C75 (20 M). Cells were fixed, stained with Nile Red, and visualized in an
epifluorescencemicroscope (A,D,G, and J) or processed for LDquantification by flow cytometry (B, E,H, and K).
Photomicrographs and panel M show LD and ADRP occurrence, respectively, in the absence of fatty acid
synthase inhibitors. Cells labeled for 24 h with 0.5 Ci/ml [3H]palmitic acid were treated as above, lipids were
separated by TLC, and [3H]TAG were quantified (C, F, I, and L). Panel N shows the correlation between TAG
synthesis and LD occurrence as induced by the six different treatments: cerulenin, C75, pH6, C2-ceramide,
tunicamycin, and glucose starvation, plus the control (closed symbols). LD inductionwith FBS did not stimulate
the synthesis of TAG (open symbol). Results in panels G–J and K–N are means S.E. from three independent
experiments. *, significantly different (p 0.01) from controls.
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ard 10% SDS-PAGE and transferred to nitrocellulose mem-
branes. Primary (1:1000) and secondary antibodies (1:5000)
were diluted in 25 mM Tris-HCl buffer, pH 7.4, containing 140
mM NaCl, 10% defatted dry milk, 0.1% bovine serum albumin,
and 0.1% Tween 20. Membranes were developed using ECL
detection reagents (Amersham Biosciences).
siRNA Transfection—We used three short interfering RNA
(siRNA) duplexes (Gene Link) designed against human iPLA2-
VIA (GenBankTM accession number AF064594): PLA2G61-
[693] (siRNA1), PLA2G62-[2295] (siRNA2), and PLA2G63-
[2641] (siRNA3), with the following sequences: 5-GAGAGA-
CCGUCUUCCAUUATT-3 (sense) and 5-TTCUCUCUGG-
CAGAAGGUAAU-3 (antisense) for siRNA1; 5-GUGACAC-
AGUGCUGGUCAATT-3 (sense) and 5-TTCACUGUGUC-
ACGACCAGUU-3 (antisense) for siRNA2; and 5-CCCUGA-
CUGUCAAGGACAATT-3 (sense), and 5-TTGGGACUGA-
CAGUUCCUGUU-3 (antisense) for siRNA3. Cells were
transfected at 60% confluence by adding to each 35-mm well 1
ml of Opti-Mem (Amersham Biosciences) containing 1.5 l of
the stock siRNA solution (20 M) and 5 l of Lipofectamine
PlusTM (1 mg/ml). After 5 h, 1 ml of Ham’s F-12 medium con-
taining 7.5% FBS was added, and the cells were incubated for
48 h, then changed to serum-free medium for 24 h prior to
treatments. When appropriate,
labeling with [3H]palmitate was
done during these 24 h.
Calcium Imaging—Cells grown
onto polylysine-coated coverslips
were incubated with the calcium
indicator Fura-2/AM at 4 M in
Krebs buffer of the following com-
position (in mM): 119 NaCl, 4.75
KCl, 5 NaHCO3, 1.2 MgSO4, 1.18
KH2PO4, 1.3 CaCl2, 20 Hepes, and 5
glucose, pH 7.4). After 1 h, cells
were washed and coverslips were
mounted in a static chamber on an
inverted Nikon TE2000U micro-
scope of a conventional epifluores-
cence system. Cells were excited
alternatively at 340 and 380 nm, and
emission light was collected at 510
nmevery 4–10 s using a 12-bit char-
ge-coupled device ERG ORCA
Hamamatsu camera. A ratio image
of cells was analyzed using the
Metafluor software (Universal
Imaging). 14–20 cellswere analyzed
in each experiment.
Phospholipase D—Cells were
labeled for 4 h with 20 Ci/ml
[32P]orthophosphate (PerkinElmer
Life Sciences), and phospholipase D
was stimulated with 100 nM phor-
bol-12-myristate-13-acetate (Cal-
biochem) and with or without 25
mM 1-butanol. To quantify phos-
phatidic acid, lipid extracts were
separated by TLC using chloroform/methanol/acetone/acetic
acid/water (50:10:20:10:5, v/v). Phosphatidylbutanol was sepa-
rated using chloroform/methanol/acetic acid (65:15:2, v/v).
[32P]Phosphatidic acid and [32P]phosphatidylbutanol were
identified by co-migration with standards made after the incu-
bation of phosphatidylcholine with cabbage phospholipase D
(Sigma-Aldrich).
Confocal Microscopy—Serum-starved cells were labeled for
24 h with 1 M C1-BODIPY 500/510-C12. After washing with
medium, cells were treated with drugs for 6 h, fixed, and pho-
tographed in a Leica TCS SP2 AOBS confocal microscope.
Statistical Analysis—Data analysis was carried out with
Prism software (GraphPad). Responses among different treat-
ments were analyzed with one-way analysis of variance fol-
lowed by the Bonferroni multiple comparison test.
RESULTS
FAS Inhibitors Induce LD and TAG Synthesis—In prelimi-
nary experiments, we observed that the inhibitors of fatty acid
synthase (FAS) cerulenin and C75 (21) induce LD biogenesis in
CHO-K1 cells. To investigate the metabolic origin of TAG, we
reasoned that stress induced by these drugs in cells kept in the
absence of serumwould provide a goodworkingmodel: de novo
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FIGURE 5. Phospholipases D and C are not involved in TAG synthesis and LD biogenesis induced by FAS
inhibitors. A, cells were treated for 6 hwith 30M cerulenin or 20M C75 in the presence or absence of 10M
U73122 or 25mM 1-butanol (ButOH), fixed, stainedwith Nile Red, and analyzed by flow cytometry. B, cells were
labeled for 24 h with 0.5 Ci/ml [3H]palmitic acid, and after the same treatments as in panel A, [3H]TAG was
quantified after TLC separation of lipid extracts. C, to assess 1-butanol effects on phospholipase D-derived
products, cells were labeled for 4 h with 2Ci/ml [32P]orthophosphate, then phospholipase Dwas stimulated
with 100 nM phorbol 12-myristate 13-acetate in the presence or absence of 25 mM 1-butanol (But). Phospha-
tidic (PtdOH, open bars) acid and phosphatidylbutanol (PtdBut, filled bars) were quantified after TLC separation
of lipid extracts. D, U73122 effect on PLC was tested in fura-2/AM-loaded cells treated sequentially with 7.5%
FBS to stimulate the generation of an inositol 1,4,5-trisphosphate-mediated calcium signal, and with 5 M
ionomycin, as indicated, in the absence (black circles) or presence (gray triangles) of 10M U73122. Results are
means S.E. of six (A) or three (B and C) independent experiments carried out with triplicate determinations.
Panel D shows an experiment representative of threewith essentially the same outcome. *, significantly differ-
ent (p 0.01) from controls.
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synthesis of fatty acids is abolished
by the treatments, and there is no
external source of lipid, making it
simpler to consider possible sources
of LD content. In these conditions,
30 M cerulenin and 20 M C75
reduced cell viability 50% over 24 h,
and inhibited acetate conversion to
fatty acids 85–90% over a 6-h treat-
ment (Fig. 1). The same 6-h treat-
ments, over the duration of time at
which cell viability was reduced 10%
as assessed by a 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium
bromide reduction assay (not
shown), induced the biogenesis of
LD and increased levels of the LD-
associated protein adipophilin
(ADRP) (Fig. 2). Indirect quantifica-
tion by flow cytometry showed that
the occurrence of LDwas about half
that found after treatment with FBS
(Fig. 2E). Unlike the induction of LD
biogenesis with FBS, which depends
on the uptake of serum lipoproteins
(7), LD induction by FAS inhibi-
tors in FBS-freemediumnecessarily
has to take place from endogenous
sources. To find out whether LD
induction by FAS inhibitors takes
place with synthesis of TAG, we
measured total TAG content and
synthesis. As shown in Fig. 3 (A and
B), treatment with cerulenin or C75
induced little (30%) but signifi-
cant increases in TAG content. The
same treatments in cells prelabeled
for 24 h with [14C]acetate or with
[3H]palmitic acid induced a 4-fold
increase in [14C]- or [3H]TAG (Fig.
3, C and D), demonstrating new
TAG synthesis from pre-existing
fatty acids. In contrast, LD induc-
tion with serum did not involve syn-
thesis of TAG from endogenous
precursors. Alkaline deacylation of
radioactive TAG confirmed its ori-
gin from pre-existing fatty acids and
that the radioactive label was not
incorporated into glycerol (Fig. 3, F
and G).
Induction of LD Biogenesis and
TAGSynthesis during Stress Does Not
Require Fatty Acid Synthesis—
The observation that LD biogenesis
and TAG synthesis occur in the
absence of fatty acid synthesis made
us consider whether this would hold
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in other models of cellular stress that do not involve the inhibi-
tion of FAS. To test this, we exposed the cells to various kinds of
stress: pH 6, which has been shown to induce LD (22, 23),
C2-ceramide, which induces cell death after the early inhibition
of phosphatidylcholine synthesis (9, 10), tunicamycin, which
inhibitsN-glycosylation and induces unfolded protein response
(24, 25) and autophagy (26), and deprivation of glucose, a con-
dition that induces apoptosis and autophagy (27–29). As shown
in Fig. 4, all the treatments induced LD and stimulated the syn-
thesis of TAG, and there was a high correlation (r2  0.952)
between TAG synthesis and LD promoted by all the stress
inducers (Fig. 4N). Treatment with stress inducers in the pres-
ence of FAS inhibitors did not decrease LD formation or TAG
synthesis but actually increased both effects. These results con-
firm that LD biogenesis and TAG synthesis during cellular
stress do not require fatty acid synthesis.
Phospholipases D and C Are Not Involved in TAG Synthesis
and LDBiogenesis during Stress—To address the origin of TAG
we considered the role of phospholipases D and C, which gen-
erate phosphatidic acid and 1,2-diacylglycerol (DAG), respec-
tively. Formation of these products could account for the incor-
poration of phospholipid-linked fatty acids into TAG, either
directly or after the action of phosphatidate phosphohydrolase
(PAP). To test this, we treated serum-starved cells with cerule-
nin or C75 and in the presence of the phospholipase C inhibitor
U73122 (30) or 1-butanol (31), which competes with water in a
phospholipase D-catalyzed transphosphatidylation reaction,
generating phosphatidylbutanol instead of phosphatidic acid.
These compounds did not affect LD biogenesis or TAG synthe-
sis (Fig. 5,A andB), yet butanol inhibited phospholipaseD-gen-
erated phosphatidic acidwhile increasing phosphatidylbutanol,
andU73122 blocked inositol 1,4,5-trisphosphate-mediated cal-
cium responses (Fig. 5, C and D).
Groups VIA and IVA Phospholipase A2 (iPLA2-VIA and
cPLA2) Are Involved in TAG Synthesis and LD Biogenesis,
Respectively—The release of fatty acids by a PLA2-mediated
processmight also account for TAG synthesis frompre-formed
fatty acids. Fig. 6A shows that treatment with cerulenin or C75
stimulated the release of AA, in a manner that was sensitive to
the cPLA2-selective inhibitor py-2 at 1 M and to the iPLA2
inhibitor BEL at 10 M, suggesting at first glance the activation
of cPLA2 and iPLA2. AA, however, was not incorporated into
TAG (Fig. 6C). In contrast, palmitic acid was not released to the
medium (Fig. 6B) but instead was used for TAG synthesis in a
manner that was inhibited by BEL but not by py-2. This phar-
macological evidence suggests the role of iPLA2 but not cPLA2
in providing fatty acids for TAG synthesis. On the other hand,
py-2 inhibited LD biogenesis induced by cerulenin or C75 (Fig.
6K). This agrees with our previous finding that LD biogenesis
from exogenous lipid requires cPLA2 (7) and further validates
it when LDs are induced by cellular stress. Interestingly, also
FIGURE 6.TAGsynthesis andLDbiogenesis during stress require the activities of iPLA2-VIAandPLA2 IVA.A–D, cellswere labeled for 24 hwith 0.5Ci/ml
[3H]arachidonic acid (A and C) or [3H]palmitic acid (B andD), washed, and treated for 6 hwith cerulenin or C75 in the absence or presence of 1Mpy-2 or 10M
BEL. A and B show radioactivity released to themedium; C andD, radioactivity in TAG. E–K, cells were treated 6 hwith cerulenin (E–G) or C75 (H–J) alone (E and
H) orwith 1Mpy-2 (F and I) or 10MBEL (G and J), fixed, stainedwithNile Red, and photographed (E–J). Alternatively, LDswere indirectly quantifiedwith flow
cytometry (K). BEL inhibition of LDbiogenesis as induced by cerulenin or C75wasmirrored by the expression of ADRP andphosphorylation of cPLA2 at Ser
505
(L). Unlike R-BEL, which was without effect, 10M S-BEL inhibited LD biogenesis (M) and TAG synthesis (N) as stimulated by cerulenin or C75. Results in A–D, K,
M, and N are means S.E. of three independent experiments each carried out in triplicate. *, significantly different (p 0.01) from controls.
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FIGURE7.Silencedexpressionof iPLA2-VIA inhibits TAGsynthesis andLD
biogenesis during stress, but it does not affect LD inductionby FBS.Cells
were transfected with siRNA as described under “Experimental Procedures,”
andmaintained in 7.5%FBS-containingmediumduring48h, then inmedium
without FBS for 24 h, either in the presence (B) or absence (A, C, and D) of 1
Ci/ml [3H]palmitate, prior to the 6-h treatments with FAS inhibitors (A–C) or
7.5%FBS (D). At the endof the 6-h treatments, radioactivity in TAG (B) and the
occurrence of LD (C and D) were quantified. Panel A shows that down-regu-
lation of iPLA2-VIA with all three siRNA is mirrored by the inhibition of LD
biogenesis, as indicatedby reducedADRP levels. *, significantly different (p
0.01) from non-treated cells transfected with control siRNA. #, significantly
different (p 0.01) from cerulenin- or C75-treated cells transfectedwith con-
trol siRNA.
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BEL inhibited LD formation in-
duced by cerulenin or C75, moni-
tored by microscopic examination
(Fig. 6, E–J), flow cytometry (Fig.
6K), or by the expression of ADRP
(Fig. 6L). Inhibition of iPLA2 also
precluded TAG synthesis and LD
biogenesis induced by acidic pH,
C2-ceramide, tunicamycin, or
deprivation of glucose (not
shown). The iPLA2 family consists
of two members in mammals,
namely Group VIA PLA2 (iPLA2-
VIA) and Group VIB PLA2
(iPLA2-VIB) (14). The S-enanti-
omer of BEL has been shown to be
more potent on iPLA2-VIA than
on iPLA2-VIB, whereas the R-iso-
mer was more potent on iPLA2-
VIB (32). In our system, 10 M
S-BEL blocked incorporation of
palmitate into TAG, and the gen-
eration of LD as stimulated by
cerulenin or C75, but the same
concentration of R-BEL was with-
out effect (Fig. 6,M andN). Taken
together, these data suggest the
implication of iPLA2-VIA in the
release of fatty acids required for
TAG synthesis in our model.
Cerulenin and C75 promoted
the phosphorylation of cPLA2
at Ser505, which is necessary for
enzyme activation during LD
biogenesis (7), and it was inhib-
ited to some degree by BEL (Fig.
6L), suggesting that iPLA2-VIA
acts upstream of cPLA2. With
this in mind, and taking into
account that cPLA2 is specific
for AA whereas iPLA2 shows no
substrate specificity for the fatty
acid at the sn-2 position (14), the
inhibition of AA release by BEL
(Fig. 6A) agrees with iPLA2-VIA
playing a cPLA2-activating role.
Down-regulation of the Expres-
sion of iPLA2-VIA Abrogates TAG
Synthesis and LD Biogenesis—A
major precursor of DAG for TAG
synthesis is phosphatidic acid,
which is dephosphorylated by
PAP. Although BEL is very specific
for the Group VI enzymes of the
PLA2 family, the drug also inhibits
PAP (18, 33, 34). A more specific
approach to inhibit iPLA2-VIA
came from the use of three siRNA
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designed against the human sequence. iPLA2-VIA occurs in
human tissues in at least five different splicing variants but only
two have enzymatic activity, termed VIA-1 and VIA-2 (14).
Although iPLA2-VIA-1 appears to be the only variant expressed
in CHO cells (35), the siRNA
sequences were designed against
the common exons to ensure down-
regulation of both variants.
As shown in Fig. 7A, all three
siRNA reduced iPLA2-VIA expres-
sion. Unlike cells transfected with
control siRNA, which when chal-
lenged with cerulenin or C75
increased expression of ADRP (Fig.
7A), synthesis of TAG (Fig. 7B), and
LD (Fig. 7C), knockdown of iPLA2-
VIA rendered the cells unrespon-
sive to cerulenin or C75 in terms of
ADRP expression (Fig. 7A), TAG
synthesis (Fig. 7B), and LD biogene-
sis (Fig. 7C), but it did not affect LD
biogenesis induced by FBS (Fig. 7D)
or increased expression of ADRP
(not shown). Again, the results show
that, unlike the paradigm of LD for-
mation from exogenous lipid,
iPLA2-VIA is required for TAG syn-
thesis taking place during LD bio-
genesis under stress.
Overexpression of iPLA2-VIA
Increases TAG Synthesis and LD
Occurrence—Transient transfec-
tion of a construct encoding a fusion
protein consisting of iPLA2-VIA2
followed by EYFP (iPLA2-VIA2-
EYFP) (Fig. 8A) increased free fatty
acid availability, as evidenced in the
presence of the acyl-CoA synthetase
inhibitor triacsinC (Fig. 8B). In con-
trast to serum-deprived GFP-trans-
fected cells, which had little LD con-
tent (Fig. 8,C and F), overexpression
of iPLA2-VIA-EYFP induced LD in
serum-deprived conditions (Fig. 8,
D and F) to levels higher than those
attained in non-transfected cells
under stress (compare with Fig. 4).
As expected, this high LD content
was abolished by 10 M BEL (Fig. 8,
E and F). Increased LD occurrence
under basal conditions in iPLA2-VI-
A-EYFP-transfected cells also mirrored the expression levels of
ADRP (Fig. 8G) and TAG synthesis (Fig. 8I). Again, increased
TAG synthesis was blocked by BEL but not by py-2 (Fig. 8I),
FIGURE 8. Overexpression of iPLA2-VIA increases TAG synthesis and LD biogenesis. Cells were transfected with GFP or with a fluorescent fusion protein
containing group VIA2 human iPLA2 followed by EYFP (GVIA2-iPLA2-EYFP), as shown in panel A. GVIA2-iPLA2-EYFP-transfected cells that were labeled 24 h with
[3H]palmitatehad increased free fattyacidcontentaftera6-h treatmentwith triacsinC (B).Unlikecells transfectedwithGFP,whichhad littleLDcontent in theabsence
of stress inducers (C), LDoccurrence inGVIA2-iPLA2-EYFP-transfectedcellswaswell apparent (D) andsensitive toBEL inhibition (E).GVIA2-iPLA2-EYFP-transfectedcells
also had increased ADRP expression that was BEL-sensitive (G). LD indirect quantification by flow cytometry (F) shows that increased LD occurrence in GVIA2-iPLA2-
EYFP-transfected cells was inhibited also by the cPLA2 inhibitor py-2. Radioactive TAG also increased in [
3H]palmitate-labeled cells (I), but unlike LD occurrence, this
effectwasnot inhibitedbypy-2. IncreasedLD inGVIA2-iPLA2-EYFP-transfectedcellswasmirroredby increasedcPLA2activity (J) andphosphorylationatSer
505 (H) that
were inhibited by BEL. Overexpression of iPLA2-VIA also enhanced LDbiogenesis (K) and TAG synthesis (L) during a 6-h treatmentwith cerulenin.
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FIGURE 9. LD content during stress is formed after iPLA2-VIA. A–D, cells were incubated during 24 h with 1
M C1-BODIPY 500/510-C12. After washing, cells were left untreated (A) or treated for 6 h with 20 M C75 (B),
C75 together with 10M BEL (C), or with 7.5% FBS (D), and visualized in the confocal microscope. E and F, after
labeling cells during 24 h with 50 Ci/ml [3H]palmitate, they were washed with medium and left untreated
(control) or treated for 6 hwith 20MC75 alone or in combinationwith 1Mpy-2. Cellswere thendisruptedby
a 10-s sonication and centrifuged 60 min at 20,000 g to obtain pellet and supernatant fractions that were
enriched in flotillin-1 and GAPDH, respectively (E). Radioactive TAG in the supernatant increased 4-fold due to
C75 treatment, but this was reduced by half after the inhibition of LD biogenesis with py-2 (F). Inset in panel F
shows that py-2 treatment did not affect total [3H]TAG. *, significantly different (p 0.05).
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whereas increased LD occurrence was inhibited by BEL and
py-2 (Fig. 8F). Importantly, overexpression of iPLA2-VIA
increased the phosphorylation of cPLA2 at Ser505 (Fig. 8H)
and the release of AA (Fig. 8J), in a BEL-sensitive fashion, the
latter effect being also sensitive to py-2. Treatment of iPLA2-
VIA-EYFP-transfected cells with cerulenin further increased
LD occurrence and TAG synthesis (Fig. 8, K and L). Taken
together, these results confirm the implication of iPLA2-VIA in
TAG synthesis and LD biogenesis, and suggest again a role for
the enzyme in the events leading to phosphorylation and acti-
vation of cPLA2.
TAGs in LD Arise from iPLA2-VIA—The previous results
demonstrate that LD biogenesis during stress takes place with
TAG synthesis after fatty acids released by iPLA2-VIA and
strongly suggest that the newly formedTAGs are present in LD.
To further assess this, we labeled cells for 24 h with the fluores-
cent fatty acid C1-BODIPY 500/
510-C12 and treated themwith C75.
As shown in Fig. 9 (A–D), C75
induced the formation of fluores-
cent LD,whereas iPLA2-VIA inhibi-
tion retained the fluorescent label
in perinuclear membranes. Simi-
larly, when LD biogenesis was
induced by FBS, which is an
iPLA2-VIA-independent process,
fluorescence remained associated
to membranes. A more direct
evidence was obtained from a
fractionation experiment in
[3H]palmitate-labeled cells: after a
24-h labeling period, LD were
induced with C75, and cells were
disrupted and centrifuged to
obtain crude supernatant and
membrane fractions. ADRP was
induced by C75 treatment, and it
was found mainly in the superna-
tant (Fig. 9E), indicating the
enrichment of this fraction in LD.
We have reported that inhibition
of cPLA2 during exogenous lipid
loading results in the retention of
TAG in membrane fractions (7).
In agreement with this, the
increase in [3H]TAG in the LD-en-
riched supernatant induced by
C75 was partially inhibited by
py-2, whereas the converse was
true regarding themembrane frac-
tion (Fig. 9F). Taken together, the
results show that TAG in LD
formed during cellular stress arise,
at least in part, from phospholipid
hydrolysis by iPLA2-VIA.
LD Biogenesis during Glucose
Deprivation May Be a Survival
Strategy—To address a physiologi-
cal significance of LD biogenesis during stress, we monitored
cell viability after deprivation of glucose under conditions that
prevent LD formation. As shown in the preceding experiments,
this can be done either by inhibiting iPLA2-VIA, which pre-
vents TAG synthesis and cPLA2 activation, or by inhibiting
cPLA2, which does not affect TAG synthesis but blocks LD
biogenesis.Other than iPLA2, BEL also inhibits PAP,which that
can account for the toxicity of this compound (12, 13). In fact, in
CHO-K1 cells maintained in serum-free medium, 10 M BEL
decreased cell viability some 70% in 8.5 h (Fig. 10A). We there-
fore chose cPLA2 inhibitionwith 1Mpy-2, which is not toxic
over a 24-h period (Fig. 10A, left panel).WhenGFP-transfected
cells were switched to glucose-free Krebs buffer, viability
decreased 30% at 8.5 h and the presence of py-2 decreased it
further 20% (Fig. 10A,middle panel). Glucose deprivation dur-
ing 8.5 h did not affect viability of cells transfected with iPLA2-
B C
D E
FIGURE 10. Cell viability during glucose deprivation is compromised after the inhibition of LD biogene-
sis. In A: Left panel, cells were treated for 8.5 or 24 h in FBS-free culture medium with 1 M py-2 (filled bars) or
with 10 M BEL (striped bars).Middle and right panels: cells transfected with GFP or with GVIA2-iPLA2-EYFP, as
indicated, were maintained in glucose-free Krebs buffer for 8.5 or 24 h, in the absence (open bars) or presence
(filled bars) of 1M py-2. In all cases, viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide reduction. B–E, cells transfected with GFP (B and C) or with GVIA2-iPLA2-EYFP (D and E) were
maintained for 20 h in glucose-free Krebs buffer, andwith (C and E) or without (B andD) 1M py-2. The images
are merged 4,6-diamidino-2-phenylindole-fluorescence and phase-contrast photomicrographs.
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VIA-EYFP (Fig. 10A, right panel), but py-2 still was toxic (Fig.
10A, right panel). Also, glucose deprivation over 20 h induced
cellular shrinkage in GFP-transfected cells (Fig. 10B), which
underwent further shrinkage and nuclear condensation in the
presence of the cPLA2 inhibitor (Fig. 10C). During glucose
starvation, py-2 also induced cellular shrinkage in iPLA2-VIA-
EYFP-transfected cells (Fig. 10E), which were morphologically
unaltered in the absence of the inhibitor (Fig. 10D). These
results suggest that LD biogenesis during glucose deprivation
has a survival effect.
DISCUSSION
Our results show that in the absence of de novo synthesis and
with no external source of fatty acids, induction of cellular
stress leads to the synthesis of TAG from pre-existing fatty
acids in a process requiring iPLA2-VIA, and to LD biogenesis,
which requires cPLA2. In contrast, induction of LD by FBS is
independent of iPLA2-VIA. Further, phosphorylation and
activity of cPLA2 decreases after iPLA2-VIA inhibition and
increases after iPLA2-VIA overexpression, suggesting that
enzyme control mechanisms for TAG synthesis and LD gener-
ation operate in a concerted manner.
LD biogenesis and synthesis of TAG is a hallmark of cellular
stress, and it was suggested that alterations in phosphatidylcho-
line metabolism could be the source of TAG (8, 36). TAG syn-
thesis takes place from DAG and a CoA-activated fatty acid, by
the action of DAG acyltransferases (37). In proliferating cells,
acetyl-CoA carboxylase and fatty acid synthase control the sup-
ply of de novo DAG, which can be converted either to TAG or
phospholipids. In fact, when phosphatidylcholine biosynthesis
decreases, TAG accumulates (38). Iorio and colleagues (8) pro-
posed that the mechanism for TAG synthesis during pro-
grammed cell death could involve a reduction in phospholipid
biosynthetic pathways and/or the activation of specific phos-
pholipases. Both mechanisms could increase DAG that would
account for LDbiogenesis at the expense of phospholipid pools.
As for the second mechanism, we show that phospholipases C
andD are not implicated. Regarding the firstmechanism, a very
early inhibition of the CDP-choline pathway for phosphatidyl-
choline synthesis has been shown to occur in some models of
toxicity with the amphiphilic drugs ET-18-OCH3 (39), hexade-
cylphosphocholine (40), or C2-ceramide (9, 10), or with cerule-
nin (38), and in fact we show that the two latter drugs induce
TAG synthesis and LD formation. Further, CHO-MT58 cells,
which express a thermosensitive CTP:phosphocholine cytidy-
lyltransferase, divert newly synthesized DAG to the TAG pool
when cultured at the restrictive temperature (38), and we have
observed that under these conditions they develop LD.6 Never-
theless, it is unlikely that all kinds of cellular stress inhibit phos-
pholipid synthesis. Also, it is difficult to envisage how cerulenin
or C75-mediated inhibition of fatty acid synthase could
increase de novo formation of DAG unless fatty acids come
from alternative sources. In this regard, our results show that
(a) fatty acid availability increases after transfection of iPLA2-
VIA, and (b) TAG synthesis takes place from pre-existing fatty
acids and is dependent on iPLA2-VIA. We have been unable,
however, to detect decreases in total phospholipids mirroring
the increase in TAG synthesis (Fig. 3E), even with an additional
24-h incubation of the cells in fresh medium after labeling with
[3H]palmitate, to allow full incorporation of the tracer (not
shown). This suggests that iPLA2-VIA provides fatty acids from
a minor phospholipid pool.
Little is known about the control iPLA2-VIA (14). Various
splice variants coexist in cells, and two of them (VIA-1 and
VIA-2) have enzymatic activity. The enzyme contains eight
(VIA-1) or seven (VIA-2) ankyrin repeats, whichmay allow oli-
gomerization and full enzymatic activity. These two variants
work similarly in our hands, because iPLA2-VIA-1 is the main
form expressed in CHO cells, and transfection of iPLA2-VIA-2
has the same effect regarding TAG synthesis for the biogenesis
of LD. Another two variants lack enzymatic activity butmay act
as dominant-negative inhibitors by precluding association of
the active variants (41). It would be interesting to determine
whether differential expression of active and inactive variants
may account for LD generation during stress. InU937 leukemia
cells undergoing apoptosis, iPLA2-VIA is cleaved by caspase-3,
generating a fragment responsible for increased activity (42).
This is not the mechanism taking place in our model, because
we have observed that (a) treatment of CHO-K1 cells with 2M
actinomycin D, which induces strong caspase-3 proteolytic
processing and activity, does not induce LD formation, and (b)
LD induction by cerulenin is not inhibited by co-treatmentwith
the pan-caspase inhibitor benzyloxycarbonyl-VAD-fluorom-
ethyl ketone at 100 M (not shown).
Among the different groups of PLA2 enzymes, iPLA2-VIA
plays a significant role in the Lands cycle of basal phospholipid
remodeling through deacylation/reacylation reactions (18, 43).
An account of the role of iPLA2-VIA in phospholipid homeo-
stasis is the observation that overexpressing CTP:phosphocho-
line cytidylyltransferase increases phosphatidylcholine content
to a much lesser extent than expected, due to accelerated deg-
radation by iPLA2-VIA, which appears to respond to excess
phospholipid synthesis (44, 45). This housekeeping role of
iPLA2-VIA,which opposes that ofCTP:phosphocholine cytidy-
lyltransferase in membrane phospholipid turnover, is impor-
tant for cell cycle progression (46). Also, iPLA2-VIA-mediated
phospholipid remodeling allows mitochondrial membrane
repair during oxidative damage (47). Release of fatty acids in
U937 cells undergoing apoptosis ismediated by iPLA2-VIA (42,
48), and in this case the enzyme works promoting cell death.
Also, overexpression of iPLA2-VIA in the same cells accelerates
apoptosis induced by oxidative stress (49). In both cases, how-
ever, pharmacological inhibition or down-regulated expression
did not rescue at longer times, showing that the enzyme is not
determinant for apoptosis. Rather, it is responsible for the gen-
eration of lysophosphatidylcholine, which is recognized by
macrophages for clearance of dying cells (13–17). Transgenic
mice expressing human iPLA2 (iPLA2-VIB) in a cardiac myo-
cyte-selective manner accumulate great amounts of TAG dur-
ing a brief caloric restriction, however this enzyme contributes
to mitochondrial dysfunction (50). Our data show that overex-
pression of iPLA2-VIA delays cell death under glucose depriva-
tion; further, preventing LD biogenesis after the inhibition of
cPLA2 opposes the protection elicited by iPLA2-VIA. Taken6 A. Riihima¨ki, M. Barcelo´-Torns, A. Gubern, and E. Claro, unpublished results.
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together, the results suggest a surviving role of LD biogenesis
during glucose deprivation.
LD biogenesis has a protecting role against lipotoxicity
derived from fatty acid accumulation (51, 52). This condition
requires the overload of high concentrations of exogenous fatty
acids and does not apply to our experimental paradigm. Mam-
mals survive starvation by activating proteolysis and lipolysis.
Other than muscle, where protein is degraded mainly by the
proteasome system and is the major source of precursors for
hepatic gluconeogenesis, fasting activates autophagy in most
tissues (53). Lipolysis, on the other hand, takes place primarily
in adipocytes, which are the major source of circulating free
fatty acids. This mechanism has received most attention over
the past years (1), but all tissues and cells types must be able to
release fatty acids from TAG packed in LD (54), conceivably to
supply local energetic needs through -oxidation. In this
regard, a recent report (55) shows that neurons from female rats
form LD and survive nutrient deprivation better than neurons
from male animals, which undergo autophagic death. Our
results agree essentially with this report, suggesting that LD
biogenesis in cells under stress may represent a lipid counter-
part of autophagy: fatty acids used for structural functions
(membrane phospholipids) could be reused for TAG synthesis
in a processmediated by iPLA2-VIA and packed in LD for ener-
getic functions in a process requiring cPLA2.
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